Teva Pharmaceutical valuation tops $40 billion in major comeback...

Economics and markets | Jul 30, 2026, 9:38 AM

Teva Pharmaceutical has reached a valuation above $40 billion after years of recovery under CEO Richard Francis.

The company’s turnaround has raised the prospect of joining the S&P 500.

PRO: see who's reacting and what you're missing. See the whole picture →